A single-arm, multicenter, phase III study to investigate the efficacy and safety of rituximab in Japanese patients with chronic immune thrombocytopenia.
Phase of Trial: Phase III
Latest Information Update: 13 May 2014
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 13 May 2014 New trial record
- 10 Dec 2013 The primary endpoint of "platelet count" has been met according to results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.